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Introduction
Eradication of Helicobacter pylori is a concern for
developing countries where prevalence of H. pylori is more
than 90% and acquisition of infection is seen at an early
age.1 Moreover, the spectrum of diseases caused by H.
pylori in the developing countries is broader than chronic
gastritis and peptic ulcer and includes conditions like
chronic diarrhea, malnutrition, and predisposition to other
enteric pathogens like typhoid and cholera.1 Recently, acute
decline in eradication rates of H. pylori has been noted and
reported from various countries primarily due to emerging
antibiotic-resistant isolates to clarithromycin and
metronidazole.2-4
The Maastricht III Consensus report recommends
triple therapy using a proton pump inhibitor (PPI) combined
with clarithromycin and amoxicillin or metronidazole as
first-line agents for the eradication of H. pylori.5
Clarithromycin resistance can drop the eradication rate up
to 58% and is frequently associated with point mutations
within the peptidyltransferase-encoding region in domain V
of the 23S rRNA (ribosomal ribonucleic acid) gene.6 The
fluoroquinolone group of antibiotics is considered an
alternative with high prevalence of clarithromycin-
resistance and is often recommended following failure with
first-line therapy. But recently resistance among this class of
antibiotic has also been reported with decline in eradication
rates, warranting the need for susceptibility testing.7
Fastidious nature and need for the sophisticated
culture techniques precludes routine susceptibility testing
for H. pylori in diagnostic laboratories in Pakistan, thus
susceptibility data is lacking from this part of the world. The
study was conducted to analyse the fluoroquinolone and
clarithromycin susceptibility pattern along with types of
genomic mutations involved in the resistance of H. pylori
isolates from Pakistan.
To the best of our knowledge, this is the first study
from Pakistan reporting the frequencies of resistance and
types of genetic mutations of clarithromycin and
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Abstract
Objective: To assess fluoroquinolone and clarithromycin susceptibility pattern along with the types of genomic
mutations involved in the resistance of Helicobacter pylori isolates.
Methods: The cross-sectional study was conducted at the Department of Pathology and Microbiology, Aga Khan
University Hospital, Karachi, from June 2009 to July 2010, and comprised 162 gastric biopsy samples which
were tested with GenoType® HelicoDR (Hain Lifescience GmbH, Germany), a reverse hybridisation multiplex
polymerase chain reaction (PCR) line probe assay (LiPA). Also, 23S rRNA (ribosomal ribonucleic acid) gene was
analysed with three-point mutations at A2146G, A2146C and A2147G for clarithromycin, and gyrA gene was
analyzed at two codon positions 87 and 91 for fluoroquinolone susceptibility testing. SPSS 19 was used for
statistical analyses.
Results: Clarithromycin resistance was seen in 60 (37.0%) of the isolates mainly involving mutation at A2147G
(85%) followed by A2146G (n=35; 21.6%) and A2146C (n=19; 11.6%). Fluoroquinolone resistance was noted in
101(62.3%) isolates, while gyrA mutations at codon 87 was seen in 64 (39.6%) and at codon 91 in 66 (40.6%).
Isolates showing combined resistance to both antibiotics were 44 (26.9%).
Conclusion: High rate of resistance to fluoroquinolones was seen despite the fact that the drug was not part of
the first-line anti-helicobacter therapy. There was moderate increase of clarithromycin resistance beyond the
cutoff rates where empirical use of this antibiotic is abandoned. The findings warrant the need for pre-treatment
susceptibility testing in Helicobacter pylori infections, especially in Pakistan where burden of disease is high and
very limited data is available, to improve patient care by providing targeted therapy. 
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fluoroquinolone using the line probe assay (LiPA)
technique.
Materials and Methods
The cross-sectional study was conducted at the
Department of Pathology and Microbiology, Aga Khan
University Hospital, Karachi (AKUH), from June 2009 to
July 2010, and comprised 162 biopsies positive for H. pylori
diagnosed on haematoxylin and eosin (H&E) staining by an
expert histopathologist. The biopsies were randomly
selected using consecutive sampling technique, and
subjected to process of DNA extraction, polymerase chain
reaction (PCR) and reverse hybridisation. Patients' clinical
information, endoscopic and histopathological findings
were also reviewed. Ethical approval for the study was
taken from the Ethics Review Committee of the AKUH.
GenoType® HelicoDR (Hain Lifescience GmbH,
Germany), a multiplex-PCR based reverse hybridisation
line probe assay (LiPA) was used in the study. The method
employs simultaneous detection of resistances to
clarithromycin and fluoroquinolone using the most common
mutations at 23SrRNA and gyrA genes for clarithromycin
and fluoroquinolone resistances respectively. This method
has been previously evaluated with reported sensitivity and
specificity of 87% and 98% respectively.8
DNA was extracted from paraffin embedded tissue
biopsy specimens using QIAamp DNA FFPE Tissue kit
(QIAGEN GmbH, Germany). A 10µm thick section of
biopsy specimen was treated with xylene with aggressive
agitation to remove paraffin from the sample and then
absolute ethanol was added to remove residual xylene. The
sample was digested using proteinase K at 56°C for 1 hour.
For partial removal of formalin, cross-linking of released
DNA (deoxyribonucleic acid) sample was then incubated at
90°C for 1 hour with Buffer ATL (animal tissue lysis).
Subsequently, the entire lysate along with ethanol was
transferred to a QIAamp MinElute Column and centrifuged
at 8,000rpm for 1min. The columns were then washed
multiple times using the commercial buffers supplied by the
manufacturers (Buffers AW1 and AW2). The DNA was
finally eluted using 55µl of ATE buffer and centrifuged at
14,000rpm to obtain purified DNA.
The protocol of amplification and hybridization was
performed in line with methods available in literature.9
Briefly, 5µl of extracted DNA was mixed with 35µl of 5'-
biotinylated primers and nucleotide mix, 5µl of 10X PCR
buffer, 2µl of 25mM MgCl 2, 3µl of molecular grade water
to make the master mix. 1U of HotStarTaq® DNA
polymerase (Qiagen GmbH, Germany) was then added to
each reaction tube. The thermal cycling profile consisted of
an initial denaturation cycle at 95°C for 15min, followed by
10 cycles at 95°C for 30sec and at 58°C for 2min. Then 25
cycles were composed of denaturation, annealing and
extension at 95°C for 25sec, 53°C for 40sec and at 70°C for
40sec respectively, followed by a final extension step at
70°C for 8min. Negative controls were run with each batch
of testing specimens. 
Hybridisation was performed using reagents
provided with Genotype® HelicoDR kit (Hain Lifescience
GmbH, Germany). For the purpose, 20µl of the PCR
product was mixed with denaturation solution and
incubated for 5min at room temperature. After placing the
DNA strips, 1ml of pre-warmed Hybridisation Buffer was
added and incubated at 45°C for 30min in TwinCubator®
(Hain Life science GmbH, Germany). After decanting the
Hybridisation Buffer completely, DNA strips were
immersed in 1ml of pre-warmed Stringent Wash Solution
and incubated at 45°C for 15min. This was followed by the
washing of DNA strips with 1ml of Rinse Solution, 1ml of
Diluted Conjugate Solution was added and DNA Strips
were incubated at room temperature for 30min. After
removal of the conjugate solution and rinsing of DNA strips
twice with the rinse solution and once with the molecular
grade water, 1ml of Diluted Substrate solution was added
and incubated at room temperature till the bands appeared
on the strips. Reaction was stopped using molecular grade
water and then DNA strips were allowed to air-dry and were
pasted on the Evaluation Sheet. Results were interpreted
using the given Evaluation Card and recorded as per the
manufacturer's recommendations.
Four control probes were available on each
GenoType® HelicoDR DNA-Strip: Conjugate control (CC)
for the efficiency of conjugate binding and substrate
reaction; amplification control (AC) for the correct
performance of the test; HP for the presence of H. pylori in
the sample; and locus controls for gyrA and 23S RNA to
detect respective gene regions.
Isolate was considered sensitive if probes for Wild
Type tested positive and there was no detectable mutation
within the examined region, whereas the absence of the
Wild Type band regardless of the presence of mutations in
any of the examined region was reported as resistant strain.
The mutation probes present on the DNA strips were only
used for epidemiological studies. 
The sample size was calculated on the basis of
previous literature. The incidence of primary macrolide
(clarithromycin) resistance is around 4-12%,5 while
fluoroquinolone resistance is reported as 2-22%.7 To
estimate the frequency of the resistance of H. pylori to
clarithromycin and fluoroquinolone, with 95% confidence
interval, level of significance (α) of 5%, an anticipated
frequency of resistance (p= 8%), and bond on the error of
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estimation of 4%, a sample size of 170 was required.
The data was analysed through SPSS version 19.0.
Frequencies and percentages were generated by cross-
tabulation for categorical variables like gender and
clarithromycin and fluoroquinolone resistance.
Results
A total of 170 paraffin embedded tissue biopsy
samples positive for H. pylori by histopathological
diagnosis on routine H&E stain were randomly selected for
the study. Of these, 8 (4.7%) samples could not be analysed
due to insufficient amount of DNA extracted. As such, 162
samples were subjected to final analysis. There were 84
(51.8%) males and 78 (48.2%) females, with age ranging
between 9 and 75 years. There was no statistically
significant difference in endoscopic and histopathological
features between clarithromycin and fluoroquinolone
sensitive and resistant groups. 
Of the 162 samples tested, 60 (37.0%) were found to
be clarithromycin-resistant, while 101 (62.3%) were found
to be fluoroquinolone-resistant, and 44 (26.9%) showed
resistance to both the antibiotics.
A total of nine gyrA gene probes were present on
each DNA strip; four corresponding to susceptible
phenotypes (Wild Types) at codon 87 (N87-AAC, N87-
AAT, T87-ACC and T87-ACT), one at codon 91 (D91-
GAT), and four corresponding to resistant phenotypes
(mutations) at positions 87 and 91 (N87K-AAA, D91N-
AAT, D91G-GGT and D91Y-TAT).
Fluoroquinolone susceptibility was assessed at two
codon positions 87 and 91. At codon 87, among the 4 Wild
Type probes WT 1 and 2 were common in the strains. WT1
(N87) was the commonest of all wild types, 30.2% (n=49),
followed by WT2 (N87) with 7.4% (n=12). None of them
had WT3 and WT4 (T87). Mutation at codon 87 was
observed in 40 (39.6%) isolates. At codon 91, MUT1
(D91N) was the most common mutation observed, 31
(30.6%) followed by MUT2 (D91G) 7 (6.9%) and MUT3
(D91Y) 3 (2.9%). Isolates not showing any signals for the
WT or mutation either at codon 87 or 91 were 20 (19.8%)
and were thus reported as fluoroquinolone-resistant strains
as per the manufacturer's recommendations (Table-1).
Four, 23S rRNA gene probes were present on each
DNA strip; one corresponding to susceptible phenotype
(Wild Type) (2146 and 2147-AA), and three corresponding
to resistant phenotypes (mutations) as A2146G, A2146C and
A2147G.
WT (2146-2147 AA) was found in 102 susceptible
strains. Among 60 resistant isolates, MUT3 (A2147G) was the
commonest 51 (85%) followed by MUT1 (A2146G) 13
(21.6%) and MUT2 (A2146C) in 7 (11.6%). The A2146C
mutation was observed only in association with other mutations.
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Table 1: Details of resistant genotypes.
Genotype n=101 (gyrA) n=60 (rrl) % Codon / Mutation Nucleotides*
gyrA gene
Codon 87 
WT1 + MUT 21 20.7 N87 + N87K
WT2 + MUT 4 3.9 N87 + N87K
WT1 + WT2 + MUT 1 0.9 N87 + N87 + N87K
MUT 14 13.8 N87K
Codon 91 
WT + MUT1 16 15.8 D91 + D91N
WT + MUT2 2 1.9 D91 + D91G
WT + MUT3 2 1.9 D91 + D91Y
MUT1 15 14.8 D91N
MUT2 5 4.9 D91G
MUT3 1 0.9 D91Y
No WT or MUT band 20 19.8
rrl gene
23S rRNA 
WT + MUT1 4 6.6 2146-2147 + A2146G
WT + MUT 2 1 1.6 2146-2147 + A2146C
WT + MUT 3 24 40 2146-2147 + A2147G
WT + MUT1 + MUT3 5 8.3 2146-2147 + A2146G + A2147G
WT + MUT2 + MUT3 4 6.6 2146-2147 + A2146C + A2147G
MUT1 2 3.3 A2146G
MUT3 14 23.3 A2146C
MUT1 + MUT3 2 3.3 A2146G + A2147G
MUT2 + MUT3 2 3.3 A2146C + A2147G
No WT or MUT band 2 3.3
*(Numbering system used in H. pylori J99 and 26695 (GenBank accession no. NC000921 and NC000915).
Two samples did not show hybridisation bands either on Wild
Type or mutation profile, suggesting unknown mutation.
A comparative analysis to assess the type of
mutations detected in H. pylori isolates from Pakistan with
those reported earlier from various parts of the world was
also done (Table-2).
Discussion
Reported clarithromycin resistance from different
parts of the world are concordant with our results - 52% in
Brazil,10 27.7% in Japan.11 In children alone, the reported
resistance is 34.4% in Austria, 36.7% in France, 39.4% in
Portugal and 49.2% in Spain.12 Study on the peri-urban
community of Karachi revealed 67% infant colonisation even
at the age of 9 months13 but interestingly in our study we had
only one sample from paediatric population, reflecting either
children being under-diagnosed or misdiagnosed or tested
with non-invasive detection methods. However, children with
upper gastrointestinal symptoms require multiple gastric
biopsies for the accurate diagnosis of organic pathology12 and
pre-treatment susceptibility testing is specially warranted in
children with areas of high prevalence. This population needs
attention in future studies from our part of the world.
The commonest mutation related to clarithromycin
resistance in our study was A2147G. Mutations with A2147G
is associated with high level of clarithromycin resistance and
lower cure rates.14 On the other hand, mutation with A2146G
have higher reported minimal inhibitory concentrations
(MICs) but clinical relevance is minimal.15
Clarithromycin resistance is moderately high in our
study, and the type of mutation responsible for its resistance in
our population is the one with more chances of treatment
failure (A2147G). Although reports from other studies
indicate different results,8,9,13,16-20 but variation in rates of
prevalence among mutations within one country has been
previously reported.10 The prevalence of mutations appears to
be different among strains of H. pylori obtained before and
after treatment with clarithromycin.15 We could not assess the
primary and secondary resistance in our isolates due to lack of
information about prior antibiotic therapy. The findings of our
study strongly recommend pre-treatment susceptibility testing
of clarithromycin as we were beyond the cutoff rates (more
than 15-20%) where clarithromycin susceptibility testing is
highly recommended.5
Fluoroquinolones are considered safe oral drugs with
good anti-helicobacter activity. Our study showed high
percentage of H. pylori isolates resistant to fluoroquinolone
although it is not a part of first-line anti-helicobacter therapy.
The results were in agreement with data published from China
reporting 55% flouroquinolone resistance in H. pylori21 and
Japan, 47.9%.22 Fluoroquinolone resistance is linked to past
use of quinolones within 10-year period, number of courses
prescribed, use in poultry industry and hospital setting.21,23
One study from Germany has reported an alarming increase in
fluoroquinolone resistance in H. pylori isolates and has linked
it with increase prescription of fluoroquinolones in the out-
patient department.24 High resistance to fluoroquinolone in
our population could also be related to increased
fluoroquinolone use for concurrent infections leading to the
emergence of resistance in H. pylori. Such consumption is
likely since infections requiring fluoroquinolone usage, such
as enteric fever and tuberculosis, are common in our region.25
Isolates that had absence of both Wild Type and mutation band
require further investigation for other mechanisms responsible
for fluoroquinolone resistance.
As there are limited numbers of drugs currently in the
pipeline for H. pylori, with such high prevalence, we have
almost lost this drug for H. pylori. For third-line therapy, there
are no current recommendations except targeted drugs that
should be checked for susceptibility before the start of
treatment like tetracyclines, rifabutin and furazolidone.
The limitation of our study was that we could not
correlate our findings with patients' prior use of antibiotics or
previous treatment failures. 
The variable resistance rates and increasing trend
towards resistance show a different geographical distribution
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Table-2: Predominant mutations responsible for clarithromycin resistance in different regions.
Region A2143G (%) A2142G (%) A2142C (%) Year Reference
Japan 22.2 66.6 0 2000 Umegaki16
Taiwan 83.3 8.3 0 2001 Yang17
Poland 69.5 17.3 8.6 2001 Dzierzanowska-fangrat18
Korea 66.7 0 0 2002 Kim19
Iran 73.6 5.2 21.5 2005 Mohammadi20
France 76 20 3 2009 Cambau8
Brazil 71.4 28.6 0 2010 Lins9
Pakistan 9 27 3 2010 Yaqoob13
Pakistan 85 21.6 11.6 2011 Current Study
and call for more region-based studies to monitor emerging
resistance.
Currently, Genotype® HelicoDR is the only available
commercial assay that checks susceptibility of both macrolide
and fluoroquinolone simultaneously. The main advantage of
this test is it can be used retrospectively on paraffin embedded
tissue samples in patients where diagnosis on histopathology
is doubtful or patient has failed empirical therapy. This study
is the first of its kind in terms of using Genotype® HelicoDR
on the paraffin embedded biopsies. As pre-treatment
susceptibility testing is cost-saving with high chances of
treatment success, this test, therefore, can be a useful tool for
both developing and developed countries.
Conclusion
The findings warrant the need for pre-treatment
susceptibility testing in H. pylori infections, especially in
Pakistan where burden of disease is high and very limited
susceptibility data is available. Although fluoroquinolones are
not part of first-line anti-helicobacter therapy, high resistance
to this group and increasing clarithromycin resistance is
alarming and warrants implementation of good antibiotic
stewardship to prevent further increase in resistance.
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